NCT02487017

DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma

Phase 2 Study of DC-CIK Cells Combined With TACE in the Treatment of Hepatocellular Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of DC-CIK cells combined TACE treatment for HCC

Detailed description

60 patients with Hepatocellular Carcinoma, who had received Transcatheter Arterial Chemoembolization (TACE) , will be randomly divided into group A (receive DC-CIK+ TACE treatment) or group B (just receive TACE), and the randomize ratio will be 1:1.

Conditions

• Hepatocellular Carcinoma
• Neoplasms
• Digestive System Neoplasms

Interventions

Type	Name	Description
PROCEDURE	Transcatheter Arterial Chemoembolization (TACE)	Transcatheter Arterial Chemoembolization (TACE): 5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min
BIOLOGICAL	DC-CIK	Transcatheter Arterial Chemoembolization (TACE): 5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min DC-CIK: 8×10\^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32

Timeline

• Start date: 2015-05-01
• Primary completion: 2018-12-01
• Completion: 2018-12-01
• First posted: 2015-07-01
• Last updated: 2016-05-24

Locations

1 site across 1 country: China